Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Nature Communications|April 21, 2021
RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathwaysVictoria Gudiño, Sebastian Öther-Gee Pohl, Caroline V Billard, et al.Nutrients|February 13, 2025
UK Patient Access to Low-Protein Prescription Foods in Phenylketonuria (PKU): An Uneasy PathSharon Evans, Cameron Arbuckle, Catherine Ashmore, et al.The Lancet. Oncology|July 6, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsClaire L Vale, David J Fisher, Peter J Godolphin, et al.The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.The Lancet. Digital Health|June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocolCharles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.Cell|August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersEmily Grist, Peter Dutey-Magni, Marina A Parry, et al.Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.Autism Research : Official Journal of the International Society for Autism Research|January 8, 2025
Demographic Correlates of Autism: How Do Associations Compare Between Diagnosis and a Quantitative Trait Measure?Kristen Lyall, Aisha S Dickerson, Annette M Green, et al.Pageof 9